Internal Medicine, Medical Oncology · Manchester, CT
NPI
1013178466
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
100 Haynes St, Second Floor
Manchester, CT, 06040
Phone (860) 646-0670
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.6M
170,741 services
Medicare patients, 2024
498
Average age 76
Drug cost, 2024
$8.3M
2,243 prescriptions
Company payments, 2025
$23.67
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joseph F McLaughlin was code J9271 (injection, pembrolizumab, 1 mg), 14,000 times for 11 patients. In total Joseph F McLaughlin billed 170,741 services in 121 codes, and Medicare paid $3.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-03-09.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,000 | 11 | $44.51 | $623K |
| J0185 Injection, aprepitant, 1 mg | Office | 11,440 | 21 | $1.35 | $15K |
| J0897 Injection, denosumab, 1 mg | Office | 5,100 | 24 | $20.49 | $104K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,920 | 33 | $0.09 | $173 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,480 | 27 | $0.72 | $1,060 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,200 | 12 | $15.87 | $19K |
| 99214 Office E&M - Established | Office | 1,096 | 376 | $98.27 | $108K |
| 96375 Injection Administration | Office | 487 | 39 | $12.64 | $6,155 |
| 96372 Injection Administration | Office | 458 | 75 | $11.58 | $5,302 |
| 96413 Chemotherapy Administration | Office | 436 | 70 | $107.23 | $47K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 258 | 33 | $4.83 | $1,246 |
| 96365 Intravenous Infusion, Hydration | Office | 169 | 69 | $49.97 | $8,445 |
| 96415 Chemotherapy Administration | Office | 130 | 26 | $23.27 | $3,026 |
| 99213 Office E&M - Established | Office | 116 | 99 | $65.09 | $7,550 |
| 96417 Chemotherapy Administration | Office | 108 | 26 | $53.97 | $5,828 |
By year: 2022 $2.4M for 93,894 services; 2023 $1.9M for 98,708 services; 2024 $3.6M for 170,741 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joseph F McLaughlin prescribed most often to Medicare patients was Anastrozole, with 248 prescriptions and refills. In total Joseph F McLaughlin wrote 2,243 Medicare prescriptions that cost $8.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 248 | 672 | 76 | $4,197 |
| Abiraterone Acetate Generic | 217 | 217 | 24 | $447K |
| Prednisone Generic | 201 | 243 | 41 | $796 |
| Eliquis Apixaban | 101 | 147 | 24 | $85K |
| Xarelto Rivaroxaban | 99 | 193 | 21 | $107K |
| Dexamethasone Generic | 97 | 101 | 34 | $1,262 |
| Revlimid Lenalidomide | 91 | 91 | 12 | $1.2M |
| Prochlorperazine Maleate Generic | 90 | 90 | 57 | $1,691 |
| Ondansetron Hcl Generic | 66 | 66 | 54 | $862 |
| Ibrance Palbociclib | 66 | 66 | Under 11 | $1.0M |
| Hydroxyurea Generic | 65 | 168 | 21 | $1,665 |
| Duloxetine Hcl Generic | 55 | 77 | Under 11 | $655 |
| Letrozole Generic | 45 | 133 | 16 | $1,259 |
| Potassium Chloride Generic | 39 | 44 | 20 | $111 |
| Acyclovir Generic | 35 | 57 | 11 | $681 |
Brand drugs: 704 claims; generic drugs: 1,539 claims; opioid claims: 57.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joseph F McLaughlin $23.67 ($23.67 in general payments such as food, travel and fees) from 2 companies. The largest payer was Novartis Pharmaceuticals Corporation with $23.67.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 1 | $23.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.